Department of Radiation Oncology (Wei JW,Xiao WW,Yu X,Guo SP,Zeng ZF,Gao YH),Department of Endoscopic Laser (Zhang R),Department of Colorectal Surgery (Cheng G,Pan ZZ,Wan DS,Ding PR),Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangzhou 510060,China
Abstract： Objective To evaluate the mid-to long-term survival benefits of preoperative sandwich-like neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC). Methods A total of 45 LARC patients who underwent neoadjuvant sandwich CRT in the form of XELOX regimen prior to,concurrently with,and following volumetric modulated arc radiotherapy (VMAT) in 2012 were enrolled in this study. VMAT was given at a gross tumor volume dose of 50 Gy in 25 fractions,and a clinical target volume dose of 45-46 Gy in 25 fractions. Total mesorectal excision was performed 6 to 8 weeks after completion of VMAT.The overall survival (OS) and disease-free survival (DFS) were determined by the Kaplan-Meier method,and survival comparison and univariate prognostic analysis were performed using the log-rank test. Results The median follow-up time was 46.7 months. There was no local recurrence detected among the patients. The 3-year distant metastasis (DM) rate was 18%,and the 3-year OS and DFS were 96% and 84%,respectively. Univariate analysis indicated that perineural invasion,N1-N2 pathology (pathological stage Ⅲ),and Ca-199>35 U/ml before treatment were risk factors for DM (P=0.000,0.000,and 0.013,respectively). Conclusions The significant short-term efficacy of preoperative sandwich-like neoadjuvant CRT can be extended to a positive mid-term survival in LARC patients. However,further phase Ⅲ clinical studies will be needed to confirm this finding.
Wei Jiawang,Zhang Rong,Xiao Weiwei et al. Mid-term outcomes of a prospective phase Ⅱ trial of preoperative sandwich-like neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 759-762.
[1] Al B,Alan P,Leonard S,et al. Clinical practice guidelines in oncology:rectal cancer V.1.2016,2015 National Comprehemsive Cancer Network[EB/OL].[2015-11-04].http://www.nccn.org. [2] Schmoll HJ.ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making[J].Ann Oncol,2012,23(10):2479-2516.DOI:10.1093/annonc/mds236. [3] 中华人民共和国卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2015版)[J].中华消化外科杂志,2015,14(10):783-799.DOI:10.3760/cma.j.issn.1673-9752.2015.10.001.Bureau of Medical Administration,National Health and Family Planning Commission of the PRC,Oncology Branch of Chinese Medical Association. Standardization of diagnosis and treatment for colorectal cancer in China (2015 edition)[J].Chin J Dig Surg,2015,14(10):783-799.DOI:10.3760/cma.j.issn.1673-9752.2015.10.001. [4] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J].N Engl J Med,2004,351(17):1731-1740.DOI:10.1056/NEJMoa040694. [5] R del C,Liersch T,Becker H,et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer:initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial[J].Lancet Oncol,2012,13(7):679-687.DOI:10.1016/S1470-2045(12) 70187-0. [6] Gao YH,Lin JZ,An X,et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to,concurrently with,and following radiation therapy in locally advanced rectal cancer:a prospective phase 2 trial[J].Int J Radiat Oncol Biol Phys,2014,90(5):1153-1160.DOI:10.1016/j.ijrobp.2014.07.021. [7] An X,Lin X,Wang FH,et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer:a meta analysis[J].Eur J Cancer,2013,49(4):843-851.DOI:10.1016/j.ejca.2012.09.026. [8] Lonardi S,Cionini L,Pinto C,et al. Distant-relapse analysis of STAR-01,a randomized phase Ⅲ trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer[J].Ann Oncol,2016,27(S2):118-128.DOI:10.1093/annonc/mdw198.19. [9] Gerard J,Gourgou-Bourgade S,Azria D,et al. ACCORD12/0405-prodige 2 phase Ⅲ trial neoadjuvant treatment in rectal cancer:results after 3 years of follow-up[J].Int J Radiat Oncol Biol Phys,2011,81(S2):S2.DOI:10.1016/j.ijrobp.2011.06.005. [10] R del C,Graeven U,Fietkau R,et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study):final results of the multicentre,open-label,randomised,phase 3 trial[J].Lancet Oncol,2015,16(8):979-989.DOI:10.1016/S1470-2045(15)00159-X. [11] Allegra CJ,Yothers G,O′Connell MJ,et al. Final results from NSABP protocol R-04:Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage Ⅱ and Ⅲ rectal cancer[A]//2014 ASCO Annual Meeting[C].Chicago:ASCO,2014:3603. [12] Chua YJ,Barbachano Y,Cunningham D,et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer:a phase 2 trial[J].Lancet Oncol,2010,11(3):241-248.DOI:10.1016/S1470-2045(09)70381-X. [13] Habr-Gama A,Perez RO,Sabbaga J,et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer:results of a prospective study using additional chemotherapy during the resting period[J].Dis Colon Rectum,2009,52(12):1927-1934.DOI:10.1007/DCR.0b013e3181ba14ed. [14] Lee S J,Kang BW,Chae YS,et al. Pilot study of neoadjuvant chemoradiotherapy with three cycles of 5-fluorouracil plus leucovorin for treatment of locally advanced rectal cancer[J].Ann Surg Oncol,2016,23(3):894-899.DOI:10.1245/s10434-015-4946-9. [15] Gao YH,Zhang X,An X,et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer[J].Strahlenther Onkol,2014,190(2):158-164.DOI:10.1007/s00066-013-0500-5. [16] Buyse M,Burzykowski T,Carroll K,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer[J].J Clin Oncol,2007,25(33):5218-5224.DOI:10.1200/JCO.2007.11.8836. [17] Montagnani F,Di Leonardo G,Pino MS,et al. Progression-free survival as a surrogate end-point in advanced colorectal cancer treated with antiangiogenic therapies[J].Anticancer Res,2016,36(8):4259-4265.
2017, Vol. 26 
